Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
   Trial
2. "Clinical trials are space travel": Factors of psychological response to recurrence among oncologists enrolling patients in treatment optimization trials.Cancer medicine · 2023
   Article
3. Physician Perspectives on Reducing Curative Cancer Treatment Intensity for Populations Underrepresented in Clinical Trials.The oncologist · 2022
   Article
4. Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.BMC cancer · 2022
   Article
5. Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer.Breast cancer research and treatment · 2021
   Article
6. Patient perspectives on chemotherapy de-escalation in breast cancer.Cancer medicine · 2021
   Article
7. Immunotherapy for Breast Cancer Treatment.Iranian biomedical journal · 2021
   Article
8. NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer.Therapeutic advances in medical oncology · 2021
   Article

Corrections and comments

• Comment on
  Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.2019

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as